The ADA is dropping its recommendation for Avandia and now recommends a back-to-basics approach for treating type 2 diabetes

The ADA is dropping its recommendation for Avandia and now recommends a back-to-basics approach for treating type 2 diabetes.

They now break diabetes therapies into two tiers...and suggest sticking with the older, cheaper ones for most patients.

Tier 1: Lifestyle changes, metformin, sulfonylureas, and insulin should be the core therapies for type 2 diabetes.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote